Analysis Of Income And Expense [Abstract]

Oxford Biomedica PLC - Filing #5873329

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	12 8,7 97 GBP	—	—	—	—	—	—	—	—	89 ,53 9 GBP	—	—	—	—	—	—
Material income and expense [abstract]
Research and development expense	—	—	4 ,54 4 GBP	—	—	—	—	—	—	—	—	11 ,4 71 GBP	—	—	—	—	—	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	—	—	7 37 GBP	—	—	—	—	—	—	—	—	5, 307 GBP	—	—	—	—	—	—
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	5 ,4 68 GBP	- GBP	4 9,3 46 GBP	- GBP	- GBP	- GBP	6 88 GBP	43 ,1 90 GBP	43 ,87 8 GBP	- GBP	3 ,86 9 GBP	18 9,4 69 GBP	2 8,1 10 GBP	- GBP	- GBP	- GBP	15 7,4 90 GBP	1 61, 35 9 GBP
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent	—	—	4 3,8 78 GBP	—	—	—	—	—	—	—	—	16 1,3 59 GBP	—	—	—	—	—	—
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests	—	—	5 ,46 8 GBP	—	—	—	—	—	—	—	—	28 ,1 10 GBP	—	—	—	—	—	—